ABSTRACT:
Amlodipine, a calcium channel blocker, is recommended as a first-line treatment for hypertension in Indonesia. However, reports from several community health centers in Indonesia indicate that long-term use of amlodipine has led to side effects such as ankle edema in a significant percentage of patients. Genetic variations in drug metabolism in an individual's body may contribute to these side effects. This study investigates the association between CYP3A5*3 and CYP3A4*1G and the incidence of peripheral edema in Indonesian amlodipine patients. This cross-sectional, analytical, observational study involved 85 peripheral blood samples from hypertensive patients. The Tetra-primer Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) method was used to identify variations in the CYP3A4*1G and CYP3A5*3 genes. The contingency coefficient analysis was conducted with IBM Statistic SPSS22 software to analyze the association of gene variants and the occurrence of peripheral edema. The incidence of edema in patients taking amlodipine occurred in 6 cases in individuals with the CYP3A4*1/*1G and CYP3A5*3/*3 genotype combination and in 3 cases in individuals with the CYP3A4*1/*1 and CYP3A5*3/3 genotype combination. However, with a p-value greater than 0.05 (p=0.536), the genotype variations did not significantly correlate with the incidence of peripheral edema. There is no association between CYP3A4*1G and CYP3A5*3 gene variation with an incidence of ankle edema in amlodipine-using patients.
Cite this article:
Sarah P. Atmaja, Paramanandhana C. S. Aji, Indah K. Sari. Effect of CYP3A4 and CYP3A5 Polymorphism on Edema Incidence in Indonesian Amlodipine Users. Research Journal of Pharmacy and Technology. 2025;18(6):2647-2. doi: 10.52711/0974-360X.2025.00380
Cite(Electronic):
Sarah P. Atmaja, Paramanandhana C. S. Aji, Indah K. Sari. Effect of CYP3A4 and CYP3A5 Polymorphism on Edema Incidence in Indonesian Amlodipine Users. Research Journal of Pharmacy and Technology. 2025;18(6):2647-2. doi: 10.52711/0974-360X.2025.00380 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-6-33
REFERENCES:
1. WHO. World Hearth Day.; 2016. https://www.who.int/cardiovascula%0Ar_diseases/world-heart-day/en/
2. Riskesdas. Laporan Nasional Riskesdas 2018 (Riskesdas (Ed.)).; 2018. http://labdata.litbang.kemkes.go.id/ccount/click.php?id=19
3. Perhimpunan Dokter Hipertensi Indonesia. Konsensus Hipertensi. Published online 2019: 118. http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf
4. Bondre S V., Chavan RS, Raut ID, Mohite SK, Magdum CS. An Overview of Survey on Antihypertensive Drugs. Asian J Pharm Res. 2020; 10(3): 160-162. doi: 10.5958/2231-5691.2020.00028.3
5. Kristanti P. Efektifitas dan Efek Samping Penggunaan Obat Antihipertensi Pada Pasien Hipertensi di Puskesmas Kalirungkut Surabaya. J Ilm Mhs Univ Surabaya. 2015; 4(2): 1-13.
6. Andhyka I, Sidrotullah M, Elvvi E. Profil Efektivitas Obat Hipertensi Captopril dan Amlodipin Pada Pasien Hipertensi Rawat Jalan di Wilayah Kerja Puskesmas Selaparang Periode Juni Tahun 2017. J Ilmu Kesehat dan Farm. 2019; 7(1): 5-9. http://ejournal.unwmataram.ac.id/jikf/article/view/566
7. Mane AK, Chaware VJ. To Assess Causality, Severity, and Preventability of Adverse drug reactions of Amlodipine in the treatment of hypertension. Asian J Res Chem. 2023; 16(1): 39-2. doi:doi: 10.52711/0974-4150.2023.00007
8. Bansal R, Mayur S, Adiga U, Rao S. Single Nucleotide Polymorphism of Leptin Receptor Gene in Type 2 Diabetes Mellitus: A Cross-sectional Study. Res J Pharm Technol. 2020; 13(2): 560-564. doi: 10.5958/0974-360X.2020.00105.5
9. Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Vol 83. 1st ed. Elsevier Inc.; 2018. doi:10.1016/bs.apha.2018.04.007
10. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102(4): 688-700. doi:10.1002/cpt.690
11. Dorji PW, Tshering G, Na-Bangchang K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. J Clin Pharm Ther. 2019; 44(4): 508-524. doi:10.1111/jcpt.12835
12. Atmaja SP, Rawar EA, Kristiyani A, Agung DA. The Genetic Polymorphisms of CYP3A4 * 1G and CYP3A5 * 3 in Javanese Indonesian Population. J Trop Life Sci. 2024; 14(1): 45-54. doi:10.11594/jtls.14.01.06.SP
13. Zhang YP, Zuo XC, Huang ZJ, et al. CYP3A5 polymorphism, amlodipine, and hypertension. J Hum Hypertens. 2014; 28(3): 145-149. doi:10.1038/jhh.2013.67
14. Liang H, Zhang X, Ma Z, et al. Association of cyp3a5 gene polymorphisms and amlodipine-induced peripheral edema in Chinese Han patients with essential hypertension. Pharmgenomics Pers Med. 2021; 14: 189-197. doi:10.2147/PGPM.S291277
15. Huang Y, Wen G, Lu Y, et al. CYP3A4∗1G and CYP3A5∗3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. Int J Clin Pharmacol Ther. 2017; 55(2): 109-118. doi:10.5414/CP202559
16. Largeau B, Cracowski JL, Lengellé C, Sautenet B, Jonville-Béra AP. Drug-induced peripheral edema: An etiology-based review. Br J Clin Pharmacol. 2021; 87(8): 3043-3055. doi:10.1111/bcp.14752
17. Hussain S, Singh A, Rahman SO, Habib A, Najmi AK. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies. Neurosci Lett. 2018; 671: 120-127. doi:10.1016/j.neulet.2018.02.027
18. Sharma D, Mehta DK, Bhatti K, Das R, Chidurala RM. Amlodipine And Atenolol: Combination Therapy Versus Monotherapy In Reducing Blood Pressure - A Focus On Safety And Efficacy. Res J Pharm Technol. 2020; 13(6): 3007-3013. doi: 10.5958/0974-360X.2020.00532.6
19. Minesh* P, Chakraborthy GS. A Role of Clinical Trial in Management of Hypertension and Medication of Hypertension. Res J Pharm Technol. 2021; 14(6): 3215. doi: 10.52711/0974-360X.2021.00560
20. Alaraj M. The effects of Amlodipine and Propranolol on Haemodialysis Efficiency in End-Stage Renal Failure Patients. Res J Pharm Technol. 2022; 15(10): 4343-4347. doi: 10.52711/0974-360X.2022.00728
21. Ramachandram DS, Chitra V, R R. Correlation of Anti-oxidant, Anti-angiogenic, and Cytotoxic activity of Tanacetum parthenium compared with Amlodipine using Chorioallantoic membrane Assay. Res J Pharm Technol. 2020; 13(4): 1665-1671. doi: 10.5958/0974-360X.2020.00302.9
22. Sangle D, Naik A, Ghorpade A, et al. Cost Effectiveness Analysis Study between Atenolol and Amlodipine in Essential Hypertension. Res J Pharm Technol. 2013; 6(9): 1001-1003.
23. Kumar Shetty K, Shetty RK, Reddy RP, Nayak V. Calcium channel blockers induced pedal edema; mechanism and treatment options: Review. Int J Sci Appl Res. 2015; 2(12): 27-33. www.ijsar.in
24. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27(4): 383-391. doi:10.1038/86882
25. Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020; 8(4). doi:10.3390/biomedicines8040094
26. Ito A, Okada Y, Hashita T, et al. Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3. Biochem Genet. 2017; 55(3): 268-277. doi:10.1007/s10528-017-9795-8
27. Pham TH, Huynh HTM, Vo HT, Tran HM. Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients. Res J Pharm Technol. 2020; 13(6): 2802-2806. doi:doi: 10.5958/0974-360X.2020.00498.9
28. Guo C, Pei Q, Tan H, Huang Z, Yuan H, Yang G. Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients. Biomed Reports. 2015; 3(2): 195-200. doi:10.3892/br.2014.395